Table 2Summary of characteristics for studies that address Key Question 1

TreatmentAuthor, Year, CountryDesign (Quality)42Number of PatientsIntervention Details100% Histopathology Confirmation (% Not Confirmed)Age, Years% Female
3DRTBogart et al, 2010, USA50Prospective (Poor)3970 Gy
17–29 frs
Yes75 (48–87)53%
Bradley et al, 2003, USA51Prospective (Fair)5670 Gy
5 frs
Yes73 (52–90)57%
Campeau et al, 2009, Australia76Retrospective (Fair)3460 Gy
30 frs
Yes81 (54–88)41%
Graham et al, 2006, Australia77Retrospective (Fair)Total: 39 (100%)
Medically inoperable: 36 (92%)
Refused surgery or NR: 3 (8%)
65 Gy
35 frs
Concurrent end-phase boost
Yes72b (53–84)38%
Jimenez et al, 2010, Spain78Retrospective (Poor)4779Gy
44 frs (calculated)
Yes68±1023%
Mirri et al, 2009, Italy54Prospective (Poor)1540 Gy
BED: 72 Gy
5 frs
No
(27%)
76bNR
Narayan et al, 2004, USA55Prospective (Poor)1392 or 103 Gy
44–49 frs (calculated)
Yes67±189%
PBRTBush et al, 2004, USA52Prospective (Good)Total: 68 (100%)
Medically inoperable: 63 (93%)
Refused surgery: 5 (7%)
51 CGE
10 frs
60 CGE
10 frs
Yes72 (52–87)56%
Iwata et al, 2010, Japan47Prospective (Good)Total: 57 (100%)
Medically inoperable: 29 (51%)
Refused surgery: 28 (49%)
80 or 60 Gy
BED: 96–112 Gy
20 frs
Yes76 (48–89)29%
Nakayama et al, 2010, Japan79Retrospective (Poor)Total: 55 (100%)
Medically inoperable: 52 (94%)
Refused surgery: 3 (6%)
66–73 GyE, 10–22 frsNo
(12%)
74±926%
RFAPennathur et al, 2007, USA80Retrospective (Good)19RF3000: power 5–10W increments until system impedance > 400 ohm
RITA: power 35–50 W, target temperature 90 degrees C
Yes78 (68–88)58%
SBRTAndratschke et al, 2011, Germany60Retrospective (Poor)9224–45 Gy
3–5 frs
Yes75 (53–93)30%
Baumann et al, 2006, Denmark62Retrospective (Poor)Total: 141 (100%)
Medically inoperable: 136 (96%)
Refused surgery: 5 (4%)
30–48 Gy
2–4 frs
No
(24%)
74 (56–90)51%
Baumann et al, 2009, Denmark 61Retrospective (Good)Total: 57 (100%)
Medically inoperable: 56 (99%)
Refused surgery: 1 (2%)
45 Gy
BED: 112 Gy
No
(33%)
75 (59–87)54%
Bollineni et al, 2012, Netherlands75Retrospective (Poor)13260 Gy
3–8 frs
No
(70%)
75 (46–90)28%
Burdick et al, 2010, USA63Retrospective (Fair)7250–60 Gy
3–10 frs
No
(32%)
73 (52–90)NR
Coon et al, 2008, USA64Retrospective (Poor)Total: 26 (100%)
Medically inoperable: 24 (92%)
Refused surgery: 2 (8%)
60 Gy
3 frs
No
(38%)
76.5aNR
Dunlap et al, 2010, USA65Retrospective (Fair)Total: 40 (100%)
Medically inoperable: 37 (92%)
Refused surgery: 3 (8%)
30–60 Gy
BED: 78–180 Gy
3–5 frs
Yes73 (54–87)NR
Fritz et al, 2008, Germany66Retrospective (Fair)Total: 40 (100%)
Medically inoperable: 37 (92%)
Refused surgery: 3 (8%)
BED: 100 GyYes74 (59–82)20%
Kopek et al, 2009, Denmark53Prospective (Good)8845 or 68 Gy
3 frs
Yes73 (47–88)49%
Nyman et al, 2006, Sweden,56Prospective (Fair)4545 Gy
3 frs
No
(20%)
74b (58–84)44%
Olsen et al, 2011, USA67Retrospective (Poor)Total: 130 (100%)
Medically inoperable: 117 (90%)
Refused surgery: 13 (10%)
45–54 Gy
3–5 frs
No
(15%)
75 (31–92)50%
Palma et al, 2011, Netherlands17Prospective (Poor)Total: 176 (100%)
Medically inoperable: 169 (96%)
Refused surgery or NR: 7 (4%)
54–64 Gy
3–8 frs
No
(68%)
70 (47–86)45%
Pennathur et al, 2009, USA68Retrospective (Fair)2120–60 Gy
BED: 60–70 Gy
1–3 frs
No
(5%)
71 (61–85)57%
Ricardi et al, 2010, Italy57Prospective (Poor)Total: 62 (100%)
Medically inoperable: 56 (90%)
Refused surgery: 6 (10%)
45 Gy
BED: 124 Gy
3 frs
No
(36%)
74b (53–83)16%
Scorsetti et al, 2007, Italy69NR (Poor)4320–32 Gy
BED: 40–117 Gy
2–4 frs
No
(5%)
75 (52–90)21%
Shibamoto et al, 2012, Japan49Prospective (Good)Total: 180 (100%)
Medically inoperable: 120 (67%)
Refused surgery: 60 (33%)
44–52 Gy
4 frs
Yes77 (29–89)32%
Song et al, 2009, Korea70Prospective (Good)Total: 32 (100%)
Medically inoperable: 31 (97%)
Refused surgery: 1 (3%)
40–60 Gy
3–4 frs
Yes72 (58–89)19%
Stephans et al, 2009, USA71Retrospective (Good)8650–60 Gy
3–5 frs
No
(29%)
73 (40–90)56%
Takeda et al, 2009, Japan48Retrospective (Fair)Total: 63 (100%)
Medically inoperable: 49 (78%)
Refused surgery: 14 (22%)
50 Gy
5 frs
No
(17%)
78 (56–91)36%
Taremi et al, 2011, Canada58Prospective (Fair)10848–60 Gy
3–10 frs
No
(29%)
73 (48–90)51
Turzer et al, 2011, Norway72Retrospective (Fair)Total: 36 (100%)
Medically inoperable: 35 (97%)
Refused surgery: 1 (3%)
45 Gy
3 frs
No
(26%)
74 (54–85)64%
Vahdat et al, 2010, USA59Prospective (Poor)2042–60 Gy
3 frs
Yes75 (64–86)80%
van der Voort van
Zyp et al, 2009, Netherlands73
NR (Poor)Total: 70 (100%)
Medically inoperable: 65 (93%)
Refused surgery: 5 (7%)
36–60 Gy
3 frs
No
(49%)
76 (54–90)NR
Videtic et al, 2010, USA74Retrospective (Fair)2650 Gy
5 frs
No
(29%)
74 (49–88)50%

3DRT = three dimensional radiotherapy; BED = biologically effective dose; CGE = cobalt gray equivalent; frs = fractions; Gy = gray; GyE = gray equivalent; NR = not reported; PBRT = proton beam radiotherapy; RFA = radiofrequency ablation; SBRT = stereotactic body radiotherapy

Values are median (range) or mean (±SD) unless specified.

a

Median.

b

Mean.

From: Results

Cover of Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non–Small-Cell Lung Cancer
Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non–Small-Cell Lung Cancer [Internet].
Comparative Effectiveness Reviews, No. 112.
Ratko TA, Vats V, Brock J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.